AR110405A1 - Compuestos - Google Patents
CompuestosInfo
- Publication number
- AR110405A1 AR110405A1 ARP170103598A ARP170103598A AR110405A1 AR 110405 A1 AR110405 A1 AR 110405A1 AR P170103598 A ARP170103598 A AR P170103598A AR P170103598 A ARP170103598 A AR P170103598A AR 110405 A1 AR110405 A1 AR 110405A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- group
- independently selected
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/009—Sachets, pouches characterised by the material or function of the envelope
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Compuesto de fórmula (1), en la que R¹ se selecciona cada uno independientemente entre el grupo que consiste en i) amino, ii) alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) ciano, v) halógeno, vi) halógenoalquilo C₁₋₆, vii) halógenoalcoxi C₁₋₆, y viii) hidroxi; R² se selecciona cada uno independientemente entre el grupo que consiste en i) amino, ii) arilo sustituido con (R³)ₖ, iii) alquilo C₁₋₆, iv) alcoxi C₁₋₆, v) alquinilo C₂₋₆ sustituido con (R⁵)ₚ, vi) ciano, vii) halógeno, viii) halógenoalquilo C₁₋₆, ix) halógenoalcoxi C₁₋₆, x) heteroarilo sustituido con (R⁴)ₗ, xi) heterociclilo sustituido con (R⁷)ʳ y xii) hidroxi; R³ se selecciona cada uno independientemente entre el grupo que consiste en i) amino, ii) alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) ciano, v) halógeno, vi) halógenoalquilo C₁₋₆, vii) halógenoalcoxi C₁₋₆, y viii) hidroxi; R⁴ se selecciona cada uno independientemente entre el grupo que consiste en i) amino, ii) alquilo C₁₋₆, iii) alcoxi C₁₋₆, iv) ciano, v) halógeno, vi) halógenoalquilo C₁₋₆, vii) halógenoalcoxi C₁₋₆, viii) heterociclilo sustituido con (R⁸)ₛ, y ix) hidroxi; R⁵ se selecciona independientemente entre el grupo que consiste en i) heteroarilo sustituido con (R⁶)q, y ii) alquilo C₁₋₆; R⁶ se selecciona independientemente entre el grupo que consiste en i) amino, y ii) alquilo C₁₋₆; R⁷ se selecciona independientemente entre el grupo que consiste en i) amino, y ii) alquilo C₁₋₆; R⁸ se selecciona independientemente entre el grupo que consiste en i) amino, y ii) alquilo C₁₋₆; Het es heteroarilo; k es 0, 1, 2 ó 3; l es 0, 1 ó 2; n es 0, 1, 2 ó 3; m es 0, 1 ó 2; p es 0, 1 ó 2; q es 0, 1 ó 2; r es 0, 1 ó 2; s es 0, 1 ó 2; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16206394 | 2016-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR110405A1 true AR110405A1 (es) | 2019-03-27 |
Family
ID=57777430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170103598A AR110405A1 (es) | 2016-12-22 | 2017-12-20 | Compuestos |
Country Status (7)
Country | Link |
---|---|
US (2) | US10882848B2 (es) |
EP (1) | EP3558967B1 (es) |
JP (1) | JP7076453B2 (es) |
CN (1) | CN110325528B (es) |
AR (1) | AR110405A1 (es) |
TW (1) | TW201834651A (es) |
WO (1) | WO2018115218A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101911090B1 (ko) * | 2011-12-27 | 2018-10-25 | 두산인프라코어 주식회사 | 인양력 증대 자세교정 장치 |
US10266517B2 (en) | 2014-12-23 | 2019-04-23 | Dana-Farber Cancer Institute, Inc. | Pyrimidines as EGFR inhibitors and methods of treating disorders |
CN110753691B (zh) * | 2017-06-02 | 2024-02-02 | 豪夫迈·罗氏有限公司 | 用于治疗性和/或预防性治疗癌症的化合物 |
EP3755689B1 (en) | 2018-02-20 | 2023-12-06 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
MX2020014085A (es) * | 2018-06-29 | 2021-03-09 | Hoffmann La Roche | Compuestos. |
WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
EP3935050A4 (en) | 2019-03-06 | 2023-01-04 | C4 Therapeutics, Inc. | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT |
TW202115074A (zh) | 2019-06-21 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | 新穎egfr抑制劑 |
AR120799A1 (es) * | 2019-12-20 | 2022-03-16 | Hoffmann La Roche | 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr |
KR20220119415A (ko) | 2019-12-20 | 2022-08-29 | 씨4 테라퓨틱스, 인코포레이티드 | Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물 |
AR120800A1 (es) * | 2019-12-20 | 2022-03-16 | Hoffmann La Roche | Derivados de 6,7-dihidro-5h-pirrolo[1,2-c]imidazol como inhibidores de egfr |
WO2021160087A1 (zh) | 2020-02-14 | 2021-08-19 | 贝达药业股份有限公司 | 喹啉基膦氧化合物及其组合物和用途 |
EP4255906A1 (en) * | 2020-12-01 | 2023-10-11 | F. Hoffmann-La Roche AG | New indazole derivatives |
WO2022117475A1 (en) * | 2020-12-01 | 2022-06-09 | F. Hoffmann-La Roche Ag | New indazole derivatives |
AR124170A1 (es) * | 2020-12-01 | 2023-02-22 | Hoffmann La Roche | Nuevos derivados de indazol acetileno |
WO2023283130A1 (en) | 2021-07-04 | 2023-01-12 | Newave Pharmaceutical Inc. | Isoquinoline derivatives as mutant egfr modulators and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2049518B1 (en) | 2006-05-31 | 2011-08-31 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents. |
CN102060848B (zh) * | 2010-12-09 | 2013-09-18 | 天津药物研究院 | 芳香胺取代的嘧啶衍生物的制备及用途 |
CN102093339B (zh) * | 2010-12-09 | 2013-06-12 | 天津药物研究院 | 一类嘧啶衍生物的制备及用途 |
EP3317273B1 (en) | 2015-06-30 | 2021-12-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
-
2017
- 2017-12-18 TW TW106144314A patent/TW201834651A/zh unknown
- 2017-12-20 AR ARP170103598A patent/AR110405A1/es unknown
- 2017-12-21 EP EP17826227.5A patent/EP3558967B1/en active Active
- 2017-12-21 WO PCT/EP2017/083969 patent/WO2018115218A1/en unknown
- 2017-12-21 CN CN201780086946.6A patent/CN110325528B/zh active Active
- 2017-12-21 JP JP2019534644A patent/JP7076453B2/ja active Active
-
2019
- 2019-06-21 US US16/449,040 patent/US10882848B2/en active Active
-
2020
- 2020-11-24 US US17/103,648 patent/US11708354B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20190308955A1 (en) | 2019-10-10 |
CN110325528A (zh) | 2019-10-11 |
US20210070739A1 (en) | 2021-03-11 |
WO2018115218A1 (en) | 2018-06-28 |
TW201834651A (zh) | 2018-10-01 |
CN110325528B (zh) | 2022-10-11 |
EP3558967B1 (en) | 2022-03-02 |
US11708354B2 (en) | 2023-07-25 |
EP3558967A1 (en) | 2019-10-30 |
JP7076453B2 (ja) | 2022-05-27 |
US10882848B2 (en) | 2021-01-05 |
JP2020502246A (ja) | 2020-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR110405A1 (es) | Compuestos | |
AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
AR092349A1 (es) | Imidazotriazincarbonitrilos utiles como inhibidores de quinasa | |
AR113929A1 (es) | Compuestos heterocíclicos | |
AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
AR100058A1 (es) | DERIVADOS DE PIRIMIDIN-PIRAZINAS FUSIONADAS MODULADORES DE RORg | |
PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
AR102204A1 (es) | Compuestos derivados de amino-alquilbenzotiazepinas | |
AR100702A1 (es) | Compuestos inhibidores de quinasa de unión tank | |
AR107973A1 (es) | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj | |
AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR109296A1 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
AR119376A1 (es) | Compuestos heterocíclicos | |
AR101255A1 (es) | Derivados de isoindolinona | |
AR109776A1 (es) | Compuestos de p2x₃ y/o p2x₂/₃ y métodos | |
AR108864A1 (es) | Agentes antibacterianos | |
AR102258A1 (es) | Compuestos de quinolina y quinazolina | |
AR112086A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
AR115936A1 (es) | Compuestos útiles en terapia del vih | |
AR111252A1 (es) | Compuestos de isoxazol carboxamida y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |